Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

Dulaglutide vs Orforglipron

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

Dulaglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Dulaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Dulaglutide's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

Dulaglutide

FDA-Approved

Orforglipron

FDA-Approved

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

Dulaglutide Orforglipron
Class GLP-1 receptor agonist Oral non-peptide GLP-1 agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism GLP-1 receptor agonist fused to human IgG4 Fc Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment [14]
Route SC injection Oral
Half-life ~5 days ~29-49 hrs
Dosage (research) 0.75 mg SC weekly (Trulicity label starting dose, escalate stepwise to 1.5, 3.0, then label max 4.5 mg weekly for additional glycemic control per AWARD trials) 0.8 mg orally once daily (FOUNDAYO label starting dose, escalate at intervals of at least 30 days through 2.5, 5.5, 9 and 14.5 mg to label max 17.2 mg once daily) [15]
Evidence tier FDA-Approved FDA-Approved
Research depth 311 indexed (PubMed 190 · CT 64 · EPMC 57) 197 indexed (PubMed 131 · CT 54 · EPMC 12)
Availability Prescription Prescription
Reported risks Nausea; diarrhea; pancreatitis risk; thyroid C-cell tumor warning GI effects; hepatic enzyme elevations

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick Dulaglutide or Orforglipron?

Dulaglutide and Orforglipron share the glp-1 class and carry roughly equivalent evidence (FDA-Approved / FDA-Approved). On the catalogued data layer Dulaglutide has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Dulaglutide's evidence base is currently denser.

What is the difference between Dulaglutide and Orforglipron?

Dulaglutide is classed as GLP-1 receptor agonist; Orforglipron is classed as Oral non-peptide GLP-1 agonist. Reported mechanism: Dulaglutide, GLP-1 receptor agonist fused to human IgG4 Fc; Orforglipron, Small-molecule non-peptide GLP-1 receptor agonist; orally bioavailable; binds the receptor upper helical bundle rather than the orthosteric peptide site; G-protein-biased partial agonist with minimal beta-arrestin recruitment. Reported half-life: Dulaglutide, ~5 days; Orforglipron, ~29-49 hrs. Routes in published studies: Dulaglutide, SC injection; Orforglipron, Oral.

Which has stronger evidence, Dulaglutide or Orforglipron?

Dulaglutide and Orforglipron sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Dulaglutide is graded FDA-Approved, with 41 cited sources on its reference page and 311 indexed studies. Orforglipron is graded FDA-Approved, with 38 cited sources on its reference page and 197 indexed studies.

Which is more accessible, Dulaglutide or Orforglipron?

Both Dulaglutide and Orforglipron are FDA-approved drugs. Catalog status: Dulaglutide, Prescription; Orforglipron, Prescription.

Are Dulaglutide and Orforglipron ever combined?

Dulaglutide and Orforglipron appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…